极晚期生物可吸收血管支架血栓形成：是烟雾还是火灾？ - Suppr | 超能文献

Very Late Bioresorbable Vascular Scaffold Thrombosis: Smoke or Fire?

作者信息

Alfonso Fernando, Cuesta Javier

机构信息

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.

Department of Cardiology, Hospital Universitario de La Princesa, Madrid, Spain.

出版信息

JACC Cardiovasc Interv. 2017 Jan 9;10(1):38-41. doi: 10.1016/j.jcin.2016.11.038.

DOI:10.1016/j.jcin.2016.11.038

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Very Late Bioresorbable Vascular Scaffold Thrombosis: Smoke or Fire?

JACC Cardiovasc Interv. 2017 Jan 9;10(1):38-41. doi: 10.1016/j.jcin.2016.11.038.

2

Very Late Bioresorbable Scaffold Thrombosis Caused by Intraluminal Scaffold Dismantling.

JACC Cardiovasc Interv. 2016 Sep 12;9(17):1844-7. doi: 10.1016/j.jcin.2016.05.041. Epub 2016 Aug 17.

3

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.

Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15.

4

Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.

5

Is the Metallic Stent a Safe Treatment for Bioresorbable Scaffold Failure?: Insights From Optical Coherence Tomography.

JACC Cardiovasc Interv. 2016 May 9;9(9):976-7. doi: 10.1016/j.jcin.2016.02.031. Epub 2016 Apr 13.

6

First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.

Circ Cardiovasc Interv. 2012 Oct;5(5):620-32. doi: 10.1161/CIRCINTERVENTIONS.112.971549. Epub 2012 Oct 9.

7

Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.

JACC Cardiovasc Interv. 2011 Dec;4(12):1271-80. doi: 10.1016/j.jcin.2011.08.016.

8

Does Asymmetric Expansion of Bioresorbable Vascular Scaffolds Cause Stent Failure?

JACC Cardiovasc Interv. 2016 Jun 27;9(12):1243-1245. doi: 10.1016/j.jcin.2016.04.026. Epub 2016 Jun 1.

9

Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.

EuroIntervention. 2016 Oct 20;12(9):1090-1101. doi: 10.4244/EIJY16M09_01.

10

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.

Int J Cardiol. 2017 Sep 15;243:121-125. doi: 10.1016/j.ijcard.2017.05.053. Epub 2017 May 12.

引用本文的文献

1

A novel paclitaxel eluting bioresorbable vascular stent with a super flexible stent structure and round cross section struts fabricated using 3D printing technology with a rotating platform.

Regen Biomater. 2025 Jul 9;12:rbaf073. doi: 10.1093/rb/rbaf073. eCollection 2025.

2

Late lumen enlargement after drug-coated balloon therapy: turning foes into friends.

EuroIntervention. 2024 May 10;20(9):523-5. doi: 10.4244/EIJ-E-24-00026.